Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lu Gan

Showing results (891-900 of 894) with videos related to

Pageof 90
Sort By:
You have reached the last page of results.This site can display upto 894 results.
The Lancet. Oncology|November 27, 2025
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trialHuiping Li, Jieqiong Liu, Quchang Ouyang, et al.
Journal of Medicinal Chemistry|November 8, 2021
Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1Jon H Come, Timothy J Senter, Michael P Clark, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Holistic Integrative Oncology|July 31, 2023
CACA Guidelines for Holistic Integrative Management of Breast CancerJiong Wu, Daiming Fan, Zhimin Shao, et al.
Pageof 90

Showing results (891-900 of 894) with videos related to

Sort By:
Pageof 90
You have reached the last page of results.This site can display upto 894 results.
The Lancet. Oncology|November 27, 2025
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trialHuiping Li, Jieqiong Liu, Quchang Ouyang, et al.
Journal of Medicinal Chemistry|November 8, 2021
Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1Jon H Come, Timothy J Senter, Michael P Clark, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Holistic Integrative Oncology|July 31, 2023
CACA Guidelines for Holistic Integrative Management of Breast CancerJiong Wu, Daiming Fan, Zhimin Shao, et al.
Pageof 90